PT1060247E - Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio - Google Patents

Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio Download PDF

Info

Publication number
PT1060247E
PT1060247E PT99909562T PT99909562T PT1060247E PT 1060247 E PT1060247 E PT 1060247E PT 99909562 T PT99909562 T PT 99909562T PT 99909562 T PT99909562 T PT 99909562T PT 1060247 E PT1060247 E PT 1060247E
Authority
PT
Portugal
Prior art keywords
nucleic acid
methods
immune response
binding agent
acid encoding
Prior art date
Application number
PT99909562T
Other languages
English (en)
Inventor
Andrew Dale Weinberg
Original Assignee
Sisters Of Providence In Orego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21845027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1060247(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sisters Of Providence In Orego filed Critical Sisters Of Providence In Orego
Publication of PT1060247E publication Critical patent/PT1060247E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT99909562T 1998-02-24 1999-02-23 Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio PT1060247E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2871698A 1998-02-24 1998-02-24

Publications (1)

Publication Number Publication Date
PT1060247E true PT1060247E (pt) 2008-12-22

Family

ID=21845027

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99909562T PT1060247E (pt) 1998-02-24 1999-02-23 Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio

Country Status (12)

Country Link
EP (2) EP1997893A1 (pt)
JP (1) JP4741074B2 (pt)
AP (1) AP1261A (pt)
AT (1) ATE408011T1 (pt)
AU (1) AU2873999A (pt)
CA (1) CA2321161C (pt)
CY (1) CY1108597T1 (pt)
DE (1) DE69939526D1 (pt)
DK (1) DK1060247T3 (pt)
ES (1) ES2315008T5 (pt)
PT (1) PT1060247E (pt)
WO (1) WO1999042585A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
ATE535249T1 (de) 2003-06-13 2011-12-15 Univ Pennsylvania Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
CA2646671A1 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
AU2014202213B2 (en) * 2007-12-14 2016-05-12 Bristol-Myers Squibb Company Binding Molecules to the Human OX40 Receptor
SI2851374T1 (sl) * 2007-12-14 2017-08-31 Bristol-Myers Squibb Company Vezavne molekule k humanemu ox40 receptorju
AU2011293558B2 (en) 2010-08-23 2014-07-31 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
MX2015010880A (es) 2013-02-22 2015-12-03 Curevac Gmbh Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
HUE034568T2 (en) 2013-03-06 2018-02-28 Astrazeneca Ab Quinazoline inhibitors for inhibiting the activation of mutant forms of epidermal growth factor receptors
MX2015013288A (es) 2013-03-18 2016-04-07 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
PT3265123T (pt) 2015-03-03 2023-02-01 Kymab Ltd Anticorpos, usos e métodos
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN108602887B (zh) 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
AU2017377036B2 (en) 2016-12-15 2022-06-23 Abbvie Biotherapeutics Inc. Anti-OX40 antibodies and their uses
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
JP2021512962A (ja) 2018-02-13 2021-05-20 アイオバンス バイオセラピューティクス，インコーポレイテッド アデノシンａ２ａ受容体アンタゴニストによる腫瘍浸潤性リンパ球（ｔｉｌ）の拡大培養並びにｔｉｌ及びアデノシンａ２ａ受容体アンタゴニストの治療的組み合わせ
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
BR112021001117A2 (pt) * 2018-07-22 2021-04-20 Health Research, Inc. células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022055399A1 (ru) * 2020-09-10 2022-03-17 Михаил Иванович Воевода Способ лечения инфекций с помощью агонистов/блокаторов рецептора ox40
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
JP2024503265A (ja) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物およびその使用の方法
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE82588T1 (de) 1986-04-28 1992-12-15 Endotronics Inc Zuchtverfahren fuer leukocyten.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5837261A (en) 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
US5665362A (en) 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
MX9601071A (es) 1995-03-23 1997-02-28 Bristol Myers Squibb Co Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales.

Also Published As

Publication number Publication date
WO1999042585A1 (en) 1999-08-26
AP1261A (en) 2004-03-19
CA2321161A1 (en) 1999-08-26
AU2873999A (en) 1999-09-06
EP1060247A1 (en) 2000-12-20
CA2321161C (en) 2011-12-20
JP2002504334A (ja) 2002-02-12
EP1060247B1 (en) 2008-09-10
EP1997893A1 (en) 2008-12-03
EP1060247B2 (en) 2011-10-26
CY1108597T1 (el) 2014-04-09
JP4741074B2 (ja) 2011-08-03
ES2315008T5 (es) 2012-03-06
DK1060247T3 (da) 2009-01-26
AP2000001903A0 (en) 2000-09-30
ATE408011T1 (de) 2008-09-15
WO1999042585A9 (en) 1999-11-04
DE69939526D1 (de) 2008-10-23
ES2315008T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
AP2000001903A0 (en) Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EP1251877A4 (en) TARGET-SPECIFIC BINDING SYSTEM, COMPOSITION AND METHOD FOR NUCLEAR IMAGING
GB9926128D0 (en) Particle manipulation
IL211075A0 (en) Multiparticulate modified release composition
IL123393A0 (en) Pesticide compositions comprising redispersible polymers
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
GB2322863B (en) Water-soluble acrylic resin,and compositions and method using it
IL145891A0 (en) Methods and compositions for modulating an immune response
EP1033127A4 (en) COMPOSITIONS FOR THE FORMATION OF SOLID-PARTICULAR PARTICLES
GB9724055D0 (en) Curable polysiloxane compositions
AU2002302070A1 (en) Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
IL126572A0 (en) Methods and compositions enhancing herbicidal company
AU8408798A (en) Methods and compositions for inhibiting the proinflammatory response
ZA984696B (en) Vaccine compositions V.
EP1071325A4 (en) COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN
HUP0200345A3 (en) Novel nucleic acid transferring agents, compositions containing them and uses
GB9508355D0 (en) Binding composition for particles nature bond
GB9929823D0 (en) Quick release compositions
GB9710904D0 (en) Neurotropin antagonist compositions
CA82608S (en) Stopper
GB9508354D0 (en) Binding composition for particles nature bond
GB9508317D0 (en) Binding composition for particles nature bond
GB9508316D0 (en) Binding composition for particles nature bond
GB9723010D0 (en) Curable polysiloxane compositions
ZA9810115B (en) Hoppers